Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Inclusion Criteria

• •1 Subjects must have histological confirmation of relapsed or refractory Hodgkin lymphoma (HL).
• •2 12 to 75 years of age.
• •3 ECOG performance of less than 2.
• •4 Life expectancy of at least 3 months.
• •5 Subjects with lymphoma must have at least one measureable lesion \>1 cm as defined by lymphoma response criteria.
• •6 Subjects must have received at least two lines of prior regimens without Anti-PD-1 antibody treatment history, and must be off therapy for at least 4 weeks prior to Day 1. Subjects with autologous hematopoietic stem-cell transplantation are eligible which must be more than 3 months.
• •7 Subjects must have adequate marrow, live, renal and heart functions.